RANKL (Galician Wikipedia)

Analysis of information sources in references of the Wikipedia article "RANKL" in Galician language version.

refsWebsite

Global rank Galician rank

19nih.gov

4^th place

6^th place

17doi.org

2^nd place

7^th place

5clinicaltrials.gov

5,225^th place

7,257^th place

3worldcat.org

5^th place

11^th place

1archive.org

6^th place

8^th place

1web.archive.org

1^st place

1cancer.org

3,680^th place

3,865^th place

archive.org

Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D, Galibert L (November 1997). "A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function". Nature 390 (6656): 175–9. PMID 9367155. doi:10.1038/36593.

cancer.org

"Hormone therapy for breast cancer". Cancer.org. Arquivado dende o orixinal o 02 de decembro de 2016. Consultado o 2014-01-31.

clinicaltrials.gov

"AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer". NCT00089674. ClinicalTrials.gov.
"Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate Cancer". NCT00321620. ClinicalTrials.gov.
"AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer". NCT00089661. ClinicalTrials.gov.
"A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects". NCT00321464. ClinicalTrials.gov.
"Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma". NCT00330759. ClinicalTrials.gov.

doi.org

dx.doi.org

Wong BR, Rho J, Arron J, Robinson E, Orlinick J, Chao M, Kalachikov S, Cayani E, Bartlett FS, Frankel WN, Lee SY, Choi Y (October 1997). "TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells". J. Biol. Chem. 272 (40): 25190–4. PMID 9312132. doi:10.1074/jbc.272.40.25190.
Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D, Galibert L (November 1997). "A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function". Nature 390 (6656): 175–9. PMID 9367155. doi:10.1038/36593.
Hanada R, Hanada T, Sigl V, Schramek D, Penninger JM (2011). "RANKL/RANK-beyond bones". J. Mol. Med. 89 (7): 647–56. PMID 21445556. doi:10.1007/s00109-011-0749-z.
Mueller CG, Hess E (2012). "Emerging Functions of RANKL in Lymphoid Tissues". Front Immunol 3: 261. PMC 3432452. PMID 22969763. doi:10.3389/fimmu.2012.00261.
Wada T, Nakashima T, Hiroshi N, Penninger JM (2006). "RANKL-RANK signaling in osteoclastogenesis and bone disease". Trends Mol Med 12 (1): 17–25. PMID 16356770. doi:10.1016/j.molmed.2005.11.007.
Xiong, Jinhu; Onal, Melda; Jilka, Robert L.; Weinstein, Robert S.; Manolagas, Stavros C.; O'Brien, Charles A. (2011-09-11). "Matrix-embedded cells control osteoclast formation". Nature Medicine 17 (10): 1235–1241. ISSN 1546-170X. PMC 3192296. PMID 21909103. doi:10.1038/nm.2448.
Xiong, Jinhu; Piemontese, Marilina; Onal, Melda; Campbell, Josh; Goellner, Joseph J.; Dusevich, Vladimir; Bonewald, Lynda; Manolagas, Stavros C.; O'Brien, Charles A. (2015-01-01). "Osteocytes, not Osteoblasts or Lining Cells, are the Main Source of the RANKL Required for Osteoclast Formation in Remodeling Bone". PLoS One 10 (9): e0138189. ISSN 1932-6203. PMC 4578942. PMID 26393791. doi:10.1371/journal.pone.0138189.
Nakashima, Tomoki; Hayashi, Mikihito; Fukunaga, Takanobu; Kurata, Kosaku; Oh-Hora, Masatsugu; Feng, Jian Q.; Bonewald, Lynda F.; Kodama, Tatsuhiko; Wutz, Anton (2011-09-11). "Evidence for osteocyte regulation of bone homeostasis through RANKL expression". Nature Medicine 17 (10): 1231–1234. ISSN 1546-170X. PMID 21909105. doi:10.1038/nm.2452.
Findlay DM, Atkins GJ (2011). "Relationship between serum RANKL and RANKL in bone". Osteoporos Int 22 (10): 2597–602. PMID 21850548. doi:10.1007/s00198-011-1740-9.
Walsh NC, Alexander KA, Manning CA, Karmakar S, Karmakar SK, Wang JF, Weyand CM, Pettit AR, Gravallese EM (2013). "Activated human T cells express alternative mRNA transcripts encoding a secreted form of RANKL". Genes Immun. 14 (5): 336–45. PMC 3740552. PMID 23698708. doi:10.1038/gene.2013.29.
O'Brien CA (2010). "Control of RANKL gene expression". Bone 46 (4): 911–9. PMC 2842447. PMID 19716455. doi:10.1016/j.bone.2009.08.050.
Coleman RE (2001). "Metastatic bone disease: clinical features, pathophysiology and treatment strategies". Cancer Treat. Rev. 27 (3): 165–76. PMID 11417967. doi:10.1053/ctrv.2000.0210.
Schmiedel BJ, Scheible CA, Nuebling T, Kopp HG, Wirths S, Azuma M, Schneider P, Jung G, Grosse-Hovest L, Salih HR (2013). "RANKL expression, function, and therapeutic targeting in multiple myeloma and chronic lymphocytic leukemia". Cancer Res. 73 (2): 683–94. PMID 23139212. doi:10.1158/0008-5472.CAN-12-2280.
Castellano D, Sepulveda JM, García-Escobar I, Rodriguez-Antolín A, Sundlöv A, Cortes-Funes H (2011). "The role of RANK-ligand inhibition in cancer: the story of denosumab". Oncologist 16 (2): 136–45. PMC 3228090. PMID 21285392. doi:10.1634/theoncologist.2010-0154.
Wood CE, Branstetter D, Jacob AP, Cline JM, Register TC, Rohrbach K, Huang LY, Borgerink H, Dougall WC (2013). "Progestin effects on cell proliferation pathways in the postmenopausal mammary gland". Breast Cancer Res. 15 (4): R62. PMC 3978455. PMID 23938070. doi:10.1186/bcr3456.
Schramek D, Leibbrandt A, Sigl V, Kenner L, Pospisilik JA, Lee HJ, Hanada R, Joshi PA, Aliprantis A, Glimcher L, Pasparakis M, Khokha R, Ormandy CJ, Widschwendter M, Schett G, Penninger JM (November 2010). "Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer". Nature 468 (7320): 98–102. PMC 3084017. PMID 20881962. doi:10.1038/nature09387.
Gonzalez-Suarez E, Jacob AP, Jones J, Miller R, Roudier-Meyer MP, Erwert R, Pinkas J, Branstetter D, Dougall WC (November 2010). "RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis". Nature 468 (7320): 103–7. PMID 20881963. doi:10.1038/nature09495.

nih.gov

ncbi.nlm.nih.gov

Wong BR, Rho J, Arron J, Robinson E, Orlinick J, Chao M, Kalachikov S, Cayani E, Bartlett FS, Frankel WN, Lee SY, Choi Y (October 1997). "TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells". J. Biol. Chem. 272 (40): 25190–4. PMID 9312132. doi:10.1074/jbc.272.40.25190.
Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D, Galibert L (November 1997). "A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function". Nature 390 (6656): 175–9. PMID 9367155. doi:10.1038/36593.
Hanada R, Hanada T, Sigl V, Schramek D, Penninger JM (2011). "RANKL/RANK-beyond bones". J. Mol. Med. 89 (7): 647–56. PMID 21445556. doi:10.1007/s00109-011-0749-z.
Mueller CG, Hess E (2012). "Emerging Functions of RANKL in Lymphoid Tissues". Front Immunol 3: 261. PMC 3432452. PMID 22969763. doi:10.3389/fimmu.2012.00261.
Wada T, Nakashima T, Hiroshi N, Penninger JM (2006). "RANKL-RANK signaling in osteoclastogenesis and bone disease". Trends Mol Med 12 (1): 17–25. PMID 16356770. doi:10.1016/j.molmed.2005.11.007.
Xiong, Jinhu; Onal, Melda; Jilka, Robert L.; Weinstein, Robert S.; Manolagas, Stavros C.; O'Brien, Charles A. (2011-09-11). "Matrix-embedded cells control osteoclast formation". Nature Medicine 17 (10): 1235–1241. ISSN 1546-170X. PMC 3192296. PMID 21909103. doi:10.1038/nm.2448.
Xiong, Jinhu; Piemontese, Marilina; Onal, Melda; Campbell, Josh; Goellner, Joseph J.; Dusevich, Vladimir; Bonewald, Lynda; Manolagas, Stavros C.; O'Brien, Charles A. (2015-01-01). "Osteocytes, not Osteoblasts or Lining Cells, are the Main Source of the RANKL Required for Osteoclast Formation in Remodeling Bone". PLoS One 10 (9): e0138189. ISSN 1932-6203. PMC 4578942. PMID 26393791. doi:10.1371/journal.pone.0138189.
Nakashima, Tomoki; Hayashi, Mikihito; Fukunaga, Takanobu; Kurata, Kosaku; Oh-Hora, Masatsugu; Feng, Jian Q.; Bonewald, Lynda F.; Kodama, Tatsuhiko; Wutz, Anton (2011-09-11). "Evidence for osteocyte regulation of bone homeostasis through RANKL expression". Nature Medicine 17 (10): 1231–1234. ISSN 1546-170X. PMID 21909105. doi:10.1038/nm.2452.
Findlay DM, Atkins GJ (2011). "Relationship between serum RANKL and RANKL in bone". Osteoporos Int 22 (10): 2597–602. PMID 21850548. doi:10.1007/s00198-011-1740-9.
Walsh NC, Alexander KA, Manning CA, Karmakar S, Karmakar SK, Wang JF, Weyand CM, Pettit AR, Gravallese EM (2013). "Activated human T cells express alternative mRNA transcripts encoding a secreted form of RANKL". Genes Immun. 14 (5): 336–45. PMC 3740552. PMID 23698708. doi:10.1038/gene.2013.29.
O'Brien CA (2010). "Control of RANKL gene expression". Bone 46 (4): 911–9. PMC 2842447. PMID 19716455. doi:10.1016/j.bone.2009.08.050.
"Entrez Gene: TNFSF11 tumor necrosis factor (ligand) superfamily, member 11".
Coleman RE (2001). "Metastatic bone disease: clinical features, pathophysiology and treatment strategies". Cancer Treat. Rev. 27 (3): 165–76. PMID 11417967. doi:10.1053/ctrv.2000.0210.
Schmiedel BJ, Scheible CA, Nuebling T, Kopp HG, Wirths S, Azuma M, Schneider P, Jung G, Grosse-Hovest L, Salih HR (2013). "RANKL expression, function, and therapeutic targeting in multiple myeloma and chronic lymphocytic leukemia". Cancer Res. 73 (2): 683–94. PMID 23139212. doi:10.1158/0008-5472.CAN-12-2280.
Castellano D, Sepulveda JM, García-Escobar I, Rodriguez-Antolín A, Sundlöv A, Cortes-Funes H (2011). "The role of RANK-ligand inhibition in cancer: the story of denosumab". Oncologist 16 (2): 136–45. PMC 3228090. PMID 21285392. doi:10.1634/theoncologist.2010-0154.
Miller PD (2009). "Denosumab: anti-RANKL antibody". Curr Osteoporos Rep 7 (1): 18–22. PMID 19239825.
Wood CE, Branstetter D, Jacob AP, Cline JM, Register TC, Rohrbach K, Huang LY, Borgerink H, Dougall WC (2013). "Progestin effects on cell proliferation pathways in the postmenopausal mammary gland". Breast Cancer Res. 15 (4): R62. PMC 3978455. PMID 23938070. doi:10.1186/bcr3456.
Schramek D, Leibbrandt A, Sigl V, Kenner L, Pospisilik JA, Lee HJ, Hanada R, Joshi PA, Aliprantis A, Glimcher L, Pasparakis M, Khokha R, Ormandy CJ, Widschwendter M, Schett G, Penninger JM (November 2010). "Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer". Nature 468 (7320): 98–102. PMC 3084017. PMID 20881962. doi:10.1038/nature09387.
Gonzalez-Suarez E, Jacob AP, Jones J, Miller R, Roudier-Meyer MP, Erwert R, Pinkas J, Branstetter D, Dougall WC (November 2010). "RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis". Nature 468 (7320): 103–7. PMID 20881963. doi:10.1038/nature09495.

web.archive.org

"Hormone therapy for breast cancer". Cancer.org. Arquivado dende o orixinal o 02 de decembro de 2016. Consultado o 2014-01-31.

worldcat.org

Xiong, Jinhu; Onal, Melda; Jilka, Robert L.; Weinstein, Robert S.; Manolagas, Stavros C.; O'Brien, Charles A. (2011-09-11). "Matrix-embedded cells control osteoclast formation". Nature Medicine 17 (10): 1235–1241. ISSN 1546-170X. PMC 3192296. PMID 21909103. doi:10.1038/nm.2448.
Xiong, Jinhu; Piemontese, Marilina; Onal, Melda; Campbell, Josh; Goellner, Joseph J.; Dusevich, Vladimir; Bonewald, Lynda; Manolagas, Stavros C.; O'Brien, Charles A. (2015-01-01). "Osteocytes, not Osteoblasts or Lining Cells, are the Main Source of the RANKL Required for Osteoclast Formation in Remodeling Bone". PLoS One 10 (9): e0138189. ISSN 1932-6203. PMC 4578942. PMID 26393791. doi:10.1371/journal.pone.0138189.
Nakashima, Tomoki; Hayashi, Mikihito; Fukunaga, Takanobu; Kurata, Kosaku; Oh-Hora, Masatsugu; Feng, Jian Q.; Bonewald, Lynda F.; Kodama, Tatsuhiko; Wutz, Anton (2011-09-11). "Evidence for osteocyte regulation of bone homeostasis through RANKL expression". Nature Medicine 17 (10): 1231–1234. ISSN 1546-170X. PMID 21909105. doi:10.1038/nm.2452.